Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Policy / Regulatory

NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations

Fineline Cube Mar 28, 2023

The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...

Company Deals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

Fineline Cube Mar 28, 2023

Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...

Company Medical Device

Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA

Fineline Cube Mar 28, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008

Fineline Cube Mar 28, 2023

Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...

Company Drug

Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review

Fineline Cube Mar 28, 2023

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...

Company

Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs

Fineline Cube Mar 28, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....

Policy / Regulatory

National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety

Fineline Cube Mar 28, 2023

The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...

Policy / Regulatory

China’s New Internet Advertising Regulations Impact Pharmaceutical Sector

Fineline Cube Mar 28, 2023

The State Administration for Market Regulation has released the latest version of the “Measures for...

Company

Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report

Fineline Cube Mar 28, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China

Fineline Cube Mar 27, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...

Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Mar 27, 2023

US-based medical device leader, Boston Scientific Corporation (NYSE: BSX), has announced the market launch of...

Policy / Regulatory

CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Development

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...

Company Deals

Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion and R&D

Fineline Cube Mar 27, 2023

China-based Huaren Pharmaceutical Co., Ltd (SHE: 300110) is set to raise capital through the private...

Policy / Regulatory

CDE Issues New Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Drugs

Fineline Cube Mar 27, 2023

The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...

Company Deals

Zhaoke Ophthalmology Signs Distribution Agreement with Kwangdong for NVK002 in South Korea

Fineline Cube Mar 27, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Gain Clinical Trial Approvals

Fineline Cube Mar 27, 2023

China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...

Company Deals

YHLO Biotech Partners with NCRCID to Develop Advanced Tuberculosis Diagnostics

Fineline Cube Mar 27, 2023

China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National...

Company Deals

Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation

Fineline Cube Mar 27, 2023

China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...

Company Deals

Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies

Fineline Cube Mar 27, 2023

China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...

Company Deals

Lee’s Pharmaceutical Subsidiary Secures Distribution Deal for NVK002 in South Korea

Fineline Cube Mar 27, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...

Posts pagination

1 … 564 565 566 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.